A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants
Condition: Multiple Sclerosis Intervention: Drug: Natalizumab Sponsor: Biogen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 27, 2023 Category: Research Source Type: clinical trials
